JP2017513515A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513515A5
JP2017513515A5 JP2017500434A JP2017500434A JP2017513515A5 JP 2017513515 A5 JP2017513515 A5 JP 2017513515A5 JP 2017500434 A JP2017500434 A JP 2017500434A JP 2017500434 A JP2017500434 A JP 2017500434A JP 2017513515 A5 JP2017513515 A5 JP 2017513515A5
Authority
JP
Japan
Prior art keywords
predetermined reference
eli
haadms
score
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017500434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513515A (ja
JP6679561B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/055992 external-priority patent/WO2015140321A1/en
Publication of JP2017513515A publication Critical patent/JP2017513515A/ja
Publication of JP2017513515A5 publication Critical patent/JP2017513515A5/ja
Application granted granted Critical
Publication of JP6679561B2 publication Critical patent/JP6679561B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017500434A 2014-03-21 2015-03-20 多発性骨髄腫におけるＨＤＡＣｉ／ＤＮＭＴｉの組み合わせに対する応答を予測する方法 Active JP6679561B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305404.7 2014-03-21
EP14305404 2014-03-21
PCT/EP2015/055992 WO2015140321A1 (en) 2014-03-21 2015-03-20 Methods for predicting response to hdaci/dnmti combination in multiple myeloma

Publications (3)

Publication Number Publication Date
JP2017513515A JP2017513515A (ja) 2017-06-01
JP2017513515A5 true JP2017513515A5 (https=) 2018-04-26
JP6679561B2 JP6679561B2 (ja) 2020-04-15

Family

ID=50434142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017500434A Active JP6679561B2 (ja) 2014-03-21 2015-03-20 多発性骨髄腫におけるＨＤＡＣｉ／ＤＮＭＴｉの組み合わせに対する応答を予測する方法

Country Status (4)

Country Link
US (1) US10662481B2 (https=)
EP (1) EP3119907B1 (https=)
JP (1) JP6679561B2 (https=)
WO (1) WO2015140321A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112074281A (zh) * 2018-03-02 2020-12-11 沃泰克斯药物股份有限公司 增强干细胞向β细胞分化的方法
CN114708963B (zh) * 2022-03-31 2025-07-15 中南大学 肺腺癌患者生存期预后评估方法、计算机装置及存储介质
CN115011694A (zh) * 2022-06-08 2022-09-06 中国科学院苏州生物医学工程技术研究所 用于鉴定样本中失调基因的方法、试剂盒
CN116953240B (zh) * 2023-08-03 2025-09-16 中国医学科学院基础医学研究所 多发性骨髓瘤的预后标志物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014056928A1 (en) 2012-10-08 2014-04-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting multiple myeloma treatment response

Similar Documents

Publication Publication Date Title
Schulze et al. Splitting the task: Ubp8 and Ubp10 deubiquitinate different cellular pools of H2BK123
Sauler et al. Macrophage migration inhibitory factor deficiency in chronic obstructive pulmonary disease
Tashkin Variations in FEV1 decline over time in chronic obstructive pulmonary disease and its implications
Wang et al. DHA inhibits protein degradation more efficiently than EPA by regulating the PPARγ/NFκB pathway in C2C12 myotubes
Mattes et al. Biomarkers of tobacco smoke exposure
Manczinger et al. Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach
JP2017513515A5 (https=)
Eckrich et al. Airway inflammation in mild cystic fibrosis
JP2009536828A5 (https=)
IL272949B2 (en) Improved treatment of atopic dermatitis with tradipitant
JP2012013082A5 (https=)
Knevel et al. Studying associations between variants in TRAF1-C5 and TNFAIP3-OLIG3 and the progression of joint destruction in rheumatoid arthritis in multiple cohorts
JP2020533381A5 (https=)
Kim et al. BCR‐ABL 1 transcript at 3 months predicts long‐term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib
RU2020133768A (ru) Способ лечения астмы или аллергического заболевания
JP2018504909A5 (https=)
Bryk et al. Early gene expression divergence between allopatric populations of the house mouse (Mus musculus domesticus)
Jeon et al. Incremental benefits of screening colonoscopy over sigmoidoscopy in average-risk populations: a model-driven analysis
van der Weyden et al. A genome-wide screen in mice to identify cell-extrinsic regulators of pulmonary metastatic colonisation
Wu et al. Cost-Effectiveness Analysis Of Ticagrelor In Treating Patients With Acute Coronary Syndrome In Hong Kong
Himes et al. Socs1 And Soc3 Modulate Immune Response In The Airway Smooth Muscle
Wu et al. IFN-β as a therapeutic agent for influenza A virus infection in old mice
Gorokhova et al. Cost-effectiveness of ranolazine for the treatment of angina pectoris in Russia
Sharp et al. What is the best initial treatment in Parkinson’s disease?
RU2023101900A (ru) СПОСОБЫ СТРАТИФИКАЦИИ ПАЦИЕНТОВ ДЛЯ ЛЕЧЕНИЯ АГОНИСТАМИ РЕЦЕПТОРОВ-α РЕТИНОЕВОЙ КИСЛОТЫ